Impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma: A prospective cohort of liver transplant candidates analysis
Transjugular intrahepatic portosystemic shunt (TIPS) is used to mitigate the side effects of portal hypertension. Its impact on hepatocellular carcinoma (HCC) remains unclear. We conducted an analysis of 43,734 liver transplant candidates with HCC from the prospective Scientific Registry of Transplant Recipients (SRTR) database between 1985-2022. A total 7,404 patients with and without TIPS were propensity score matched 1:3. We assessed wait-list changes in total tumor volume, number of HCC , and alpha-fetoprotein levels. We examined survival rates from time of listing and post-transplantation, as well as the incidence of HCC recurrence post-transplantation. Before matching, patients with TIPS exhibited poorer liver function and less advanced HCCs compared to patients without TIPS. After matching, TIPS was associated with a decrease in the number of HCC nodules (-0.24 vs 0.11, p = 0.008) over a median waiting period of 225 days (IQR 94; 441) and a better overall survival rate from listing (93.0% vs 89.1% at one year, p = 0.0003). TIPS was not associated with altered changes in waitlist tumor volume (0.26 vs -0.07 cm3/month, p = 0.26) and AFP (14.62 vs 12.67 ng/mL, p = 0.79) compared to the non-TIPS group. Both post-transplant survival rates (91.8% vs 91.7% at one year, p = 0.25) and incidence of HCC recurrence (5.2% vs 5.4% at 5 years, p = 0.73) were similar between groups with a median follow-up duration of 5.6 years (IQR 2.7; 9.6). TIPS is associated with improved waitlist survival and a reduction in the number of HCC , potentially due to a better efficacy in HCC treatment. However, TIPS did not have a measurable impact on HCC growth or aggressiveness.
- Organizational unit
- Transplantation and Hepatology Laboratory
- Type
- Dataset
- DOI
- Referenced by the following DOI or ARK
- License
- Creative Commons Attribution-NonCommercial 4.0 International
- Keywords
- Transjugular intrahepatic portosystemic shunt, Liver transplantation, Recurrence, Survival, Progression, Hepatocellular carcinoma
License
Contributors
- TOSO, Christian
- Lacotte, Stéphanie
- Moeckli, Beat
- El Hajji, Sofia
Quality (0 Reviews) Usefulness (0 Reviews)
Datacite metadata
<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<datacite:resource xmlns:premis="http://www.loc.gov/premis/v3" xmlns:mets="http://www.loc.gov/METS/" xmlns:datacite="http://datacite.org/schema/kernel-4" xmlns:dlcm="http://www.dlcm.ch/dlcm/v2" xmlns:fits="http://hul.harvard.edu/ois/xml/ns/fits/fits_output" xmlns:xlink="http://www.w3.org/1999/xlink">
<datacite:identifier identifierType="DOI">10.26037/yareta:4q74hn6kbjgkji5ktto55cmzz4</datacite:identifier>
<datacite:creators>
<datacite:creator>
<datacite:creatorName nameType="Personal">TOSO, Christian</datacite:creatorName>
<datacite:givenName>Christian</datacite:givenName>
<datacite:familyName>TOSO</datacite:familyName>
</datacite:creator>
<datacite:creator>
<datacite:creatorName nameType="Personal">Lacotte, Stéphanie</datacite:creatorName>
<datacite:givenName>Stéphanie</datacite:givenName>
<datacite:familyName>Lacotte</datacite:familyName>
<datacite:nameIdentifier xsi:type="datacite:nameIdentifier" nameIdentifierScheme="ORCID" schemeURI="https://orcid.org/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">0000-0002-5921-6389</datacite:nameIdentifier>
</datacite:creator>
<datacite:creator>
<datacite:creatorName nameType="Personal">Moeckli, Beat</datacite:creatorName>
<datacite:givenName>Beat</datacite:givenName>
<datacite:familyName>Moeckli</datacite:familyName>
<datacite:nameIdentifier xsi:type="datacite:nameIdentifier" nameIdentifierScheme="ORCID" schemeURI="https://orcid.org/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">0000-0002-9020-8416</datacite:nameIdentifier>
</datacite:creator>
<datacite:creator>
<datacite:creatorName nameType="Personal">El Hajji, Sofia</datacite:creatorName>
<datacite:givenName>Sofia</datacite:givenName>
<datacite:familyName>El Hajji</datacite:familyName>
<datacite:nameIdentifier xsi:type="datacite:nameIdentifier" nameIdentifierScheme="ORCID" schemeURI="https://orcid.org/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">0000-0002-3028-6148</datacite:nameIdentifier>
</datacite:creator>
</datacite:creators>
<datacite:titles>
<datacite:title>Impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma: A prospective cohort of liver transplant candidates analysis</datacite:title>
</datacite:titles>
<datacite:publisher>Université de Genève, Yareta</datacite:publisher>
<datacite:publicationYear>2023</datacite:publicationYear>
<datacite:resourceType resourceTypeGeneral="Dataset">Dataset</datacite:resourceType>
<datacite:subjects>
<datacite:subject subjectScheme="keywords">Transjugular intrahepatic portosystemic shunt;Liver transplantation;Recurrence;Survival;Progression;Hepatocellular carcinoma</datacite:subject>
</datacite:subjects>
<datacite:contributors>
<datacite:contributor contributorType="ResearchGroup">
<datacite:contributorName nameType="Organizational">[22639399-279e-4c4b-9fd8-7d009db8ced5] Transplantation and Hepatology Laboratory</datacite:contributorName>
<datacite:affiliation xsi:type="datacite:affiliation" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">[UNIGE-Medecine] Université de Genève - Faculté de Médecine</datacite:affiliation>
<datacite:affiliation xsi:type="datacite:affiliation" affiliationIdentifier="https://ror.org/01swzsf04" affiliationIdentifierScheme="ROR" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">[UNIGE] Université de Genève</datacite:affiliation>
</datacite:contributor>
<datacite:contributor contributorType="ProjectManager">
<datacite:contributorName nameType="Personal">Lacotte, Stéphanie</datacite:contributorName>
</datacite:contributor>
</datacite:contributors>
<datacite:dates>
<datacite:date dateType="Issued">2023-12-11T00:00:00Z</datacite:date>
<datacite:date dateType="Collected">1985-01-01T01:00:00Z/2022-01-01T01:00:00Z</datacite:date>
<datacite:date dateType="Created">2023-12-11T17:01:24.580409Z</datacite:date>
<datacite:date dateType="Updated">2025-10-09T07:56:21.800398Z</datacite:date>
<datacite:date dateType="Accepted">2025-10-08T09:46:48.007976231Z</datacite:date>
</datacite:dates>
<datacite:alternateIdentifiers>
<datacite:alternateIdentifier alternateIdentifierType="ARK">ark:/64642/rt94q74hn6kbjgkji5ktto55cmzz4</datacite:alternateIdentifier>
</datacite:alternateIdentifiers>
<datacite:relatedIdentifiers>
<datacite:relatedIdentifier relatedIdentifierType="DOI" relationType="IsReferencedBy">10.3389/ti.2024.12781</datacite:relatedIdentifier>
</datacite:relatedIdentifiers>
<datacite:formats>
<datacite:format>text/plain</datacite:format>
<datacite:format>application/pdf</datacite:format>
<datacite:format>text/xml</datacite:format>
</datacite:formats>
<datacite:rightsList>
<datacite:rights rightsURI="https://www.dlcm.ch/access-level/final">PUBLIC</datacite:rights>
<datacite:rights rightsURI="https://www.dlcm.ch/data-tag">BLUE</datacite:rights>
<datacite:rights rightsURI="https://www.dlcm.ch/data-use-policy">LICENSE</datacite:rights>
<datacite:rights rightsURI="https://creativecommons.org/licenses/by-nc/4.0/" rightsIdentifier="CC-BY-NC-4.0" rightsIdentifierScheme="SPDX">Creative Commons Attribution-NonCommercial 4.0 International</datacite:rights>
</datacite:rightsList>
<datacite:descriptions>
<datacite:description descriptionType="Abstract">Transjugular intrahepatic portosystemic shunt (TIPS) is used to mitigate the side effects of portal hypertension. Its impact on hepatocellular carcinoma (HCC) remains unclear.
We conducted an analysis of 43,734 liver transplant candidates with HCC from the prospective Scientific Registry of Transplant Recipients (SRTR) database between 1985-2022. A total 7,404 patients with and without TIPS were propensity score matched 1:3. We assessed wait-list changes in total tumor volume, number of HCC , and alpha-fetoprotein levels. We examined survival rates from time of listing and post-transplantation, as well as the incidence of HCC recurrence post-transplantation.
Before matching, patients with TIPS exhibited poorer liver function and less advanced HCCs compared to patients without TIPS. After matching, TIPS was associated with a decrease in the number of HCC nodules (-0.24 vs 0.11, p = 0.008) over a median waiting period of 225 days (IQR 94; 441) and a better overall survival rate from listing (93.0% vs 89.1% at one year, p = 0.0003). TIPS was not associated with altered changes in waitlist tumor volume (0.26 vs -0.07 cm3/month, p = 0.26) and AFP (14.62 vs 12.67 ng/mL, p = 0.79) compared to the non-TIPS group. Both post-transplant survival rates (91.8% vs 91.7% at one year, p = 0.25) and incidence of HCC recurrence (5.2% vs 5.4% at 5 years, p = 0.73) were similar between groups with a median follow-up duration of 5.6 years (IQR 2.7; 9.6).
TIPS is associated with improved waitlist survival and a reduction in the number of HCC , potentially due to a better efficacy in HCC treatment. However, TIPS did not have a measurable impact on HCC growth or aggressiveness.
</datacite:description>
</datacite:descriptions>
<datacite:fundingReferences/>
</datacite:resource>
Packages information
- Metadata version
- 3.1
- Disposal approval
- Yes
- Retention expiration
- 08/12/2033 00:00:00
- Created
- 08/10/2025 09:46:48
- Deposit
- Impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma: A prospective cohort of liver transplant candidates analysis
- Deposit creation
- Deposit approval
- 09/10/2025 07:56:21
- SIP
- Impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma: A prospective cohort of liver transplant candidates analysis
- AIP
- Impact of transjugular intrahepatic portosystemic shunt on hepatocellular carcinoma: A prospective cohort of liver transplant candidates analysis
- Agent 1
- Linux | amd64 | 4.18.0-553.47.1.el8_10.x86_64
- Agent 2
- Eclipse Adoptium | Software | 21.0.8
- Agent 3
- DLCM | Software | 3.1.0
- Agent 4
- FITS | Software | 1.6.0
- Agent 5
- ClamAV | Software | 1.4.2
Similar archives
Transplantation and Hepatology Laboratory
Transplantation and Hepatology Laboratory
Transplantation and Hepatology Laboratory
Transplantation and Hepatology Laboratory

